Biosimilars
Biosimilar medicines:
We believe that biosimilar medicines represent a significant opportunity for the NHS and patients, and we are working with healthcare professionals and commissioners to help realise their potential and make a positive difference to patients.
Great Britain – Herzuma®▼ (trastuzumab) 150 mg powder for concentrate for solution for infusion
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
SPC PIL
Northern Ireland – Herzuma®▼ (trastuzumab) 150 mg powder for concentrate for solution for infusion
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
SPC PILGreat Britain – Herzuma®▼ (trastuzumab) 420 mg powder for concentrate for solution for infusion
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
SPC PILNorthern Ireland – Herzuma®▼ (trastuzumab) 420 mg powder for concentrate for solution for infusion
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
SPC PILTruxima®▼ (rituximab) 100 mg concentrate for solution for infusion
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
SPC PIL
Truxima®▼ (rituximab) 500 mg concentrate for solution for infusion
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
SPC PIL
Pelmeg®▼ (pegfilgrastim) 6 mg solution for injection in pre-filled syringe
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
SPC PIL